You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
AstraZeneca
Baxter
Mallinckrodt

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

REPATHA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for REPATHA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AmgenN/A
Radboud UniversityN/A
LIB Therapeutics LLCPhase 3

See all REPATHA clinical trials

Recent Litigation for REPATHA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Amgen Inc. v. Sanofi2017-01-12

See all REPATHA litigation

Pharmacology for REPATHA
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionPCSK9 Inhibitors

Company Disclosures: US Patents for REPATHA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen, Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen, Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
Amgen Inc REPATHA evolocumab INJECTABLE;INJECTION 125522 001 2016-07-08   Start Trial Amgen Inc. (Thousand Oaks, CA) 2027-08-23 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for REPATHA

These patents were identified by searching patent claims

Supplementary Protection Certificates for REPATHA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1690035-9 Sweden   Start Trial PRODUCT NAME: ALIROKUMAB; REG. NO/DATE: EU/1/15/1031 20150925
PA2016021 Lithuania   Start Trial PRODUCT NAME: EVOLOCUMABUM; REGISTRATION NO/DATE: EU1/15/1016 20150717
122016000042 Germany   Start Trial PRODUCT NAME: EVOLOCUMAB; REGISTRATION NO/DATE: EU/1/15/1016 20150717
93096 Luxembourg   Start Trial PRODUCT NAME: EVOLOCUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (REPATHA); FIRST REGISTRATION DATE: 20150721
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
McKesson
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.